✦ LIBER ✦

Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

✍ Scribed by Carolyn N. Krasner; Andres Poveda; Thomas J. Herzog; Jan B. Vermorken; Stanley B. Kaye; Antonio Nieto; Pilar Lardelli Claret; Youn Choi Park; Trilok Parekh; Bradley J. Monk

Book ID: 118506693
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 553 KB
Volume: 127
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2012.06.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trial in progress: A randomized double-b

Trial in progress: A randomized double-blind phase 3 trial comparing vintafolide+pegylated liposomal doxorubicin (PLD) versus PLD+placebo in patients with platinum-resistant ovarian cancer (PROCEED)

✍ Naumann, R.W.; Gilbert, L.; Habbe, A.; Ma, H.; Ghamande, S.; Vergote, I.B. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Addition of vandetanib to pegylated lipo

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

✍ Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, JÃ¶rn; Hilpert, Felix; Kur 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 162 KB

Trabectedin plus pegylated liposomal dox

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

✍ Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-C 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 536 KB

Trabectedin plus pegylated liposomal dox

✍ Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-C 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 536 KB

18LBA A GCIG randomized phase III study

18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients

✍ P. Vasey; R. Largillier; M. Gropp; V. Gebski; R. Sandvei; L. Elit; L. Angleitner 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB